

REVIEW

Complications following oesophagectomy, a review with future perspectives

M. Buise¹, B. Kantering¹, J. van Bommel²

¹Department of Anaesthesia, Pain Management and Intensive Care Medicine, Catharina Hospital Eindhoven, the Netherlands

²Departement of Intensive Care Medicine, Erasmus Mc, Rotterdam

Correspondence

M. Buise – e-mail: marc.buise@catharinaziekenhuis.nl

Keywords – Oesophagectomy, gastric tube reconstruction, complications

Abstract

Oesophagectomy with gastric tube reconstruction is a complex, high-risk surgical procedure. Despite improvements in surgical techniques and perioperative care, the postoperative course is often complicated. The two most frequent and important complications following oesophagectomy are anastomotic failure and pulmonary morbidity.

Along with surgical methods, microvascular blood flow is an important factor in the development of anastomotic failure. Location of the anastomosis, tissue supportive techniques and early detection of anastomotic leakage may contribute to a decrease in morbidity.

The pathogenesis of pulmonary complications is multifactorial. Prolonged systemic inflammatory response syndrome responses are associated with pulmonary complications. The cholinergic anti-inflammatory pathway may play a role in this inflammatory response and future research in this direction is necessary in the search for better care.

In our opinion, only clinical pathways that include early extubation, fluid management, pain management and early mobilization and nutrition, are providing opportunities for fewer postoperative pulmonary complications. However, clinical pathways succeed only if surgeons, anaesthetists and intensivists feel they are part of the treatment process and take responsibility as a team for all complications.

Introduction

Oesophagectomy with gastric tube reconstruction is a complex and high-risk surgical procedure. Despite improvements in surgical techniques and perioperative care, the postoperative course is often complicated.^{1,2} Complications following oesophagectomy can be divided into two categories, firstly surgical and secondly medical. Unlike any other oncological or gastro-intestinal operation, oesophagectomy is associated with numerous non-surgical complications. It is unclear why patients are more vulnerable following oesophagectomy

than patients following, for example, a pneumonectomy or pancreatic surgery.

The complexity, morbidity and in-hospital mortality rates have led to national and international discussion for the need for centralization of oesophageal surgery. Although complication rates are similar in lower and higher volume hospitals, it is more likely that high volume centres treat complications more successfully.^{3,4} An increase in volume of this procedure has led to a better understanding and regulation of the infrastructure of the management of patients. The introduction of clinical pathways may help improve the infrastructure surrounding patients following oesophagectomy and also improve complications.⁵⁻⁷

In the following section we discuss the two most frequent and important complications following an oesophagectomy: anastomotic failure and pulmonary morbidity.

Gastroesophageal anastomotic failure

For an acceptable quality of life for patients after radical curative oesophageal resection, continuity of the gastrointestinal tract is necessary. Of all the conduits (colon, jejunum and stomach) gastric tube reconstruction is the one used most often internationally. The gastric tube is constructed by ligating the left and right gastric arteries, the short gastric arteries and the left gastroepiploic artery. These are then fashioned along the greater curvature of the stomach. The fundus side of the gastric tube depends on the right gastroepiploic arterial arcade for arterial supply.⁸ In the literature, leakage of the gastroesophageal anastomosis occurs in 0% to 35% patients. The wide range is partly due to the various definitions used for anastomotic leakage. In a recent review of 80 articles on complications following gastric tube reconstruction, 25 different definitions were used for anastomotic leakage.⁹

Compromised microvascular blood flow of the gastric tube, as a result of ligation of the main arteries, is thought to be an important factor in the pathogenesis of anastomotic failure. By vascular conditioning due to endovascular coiling or

laparoscopic clipping of the depending arteries prior to gastric tube reconstruction, stimulation of collateral perfusion of the gastric tissue might be achieved. These techniques are currently being evaluated in research protocols. Large series, and therefore results on outcome, have not yet been published.¹⁰ Other studies have tried to improve arterial circulation by creating vascular anastomosis of the short gastric vessels with vessels in the neck. A remarkable observation was made in the improvement of microcirculation after creating only the venous anastomosis, suggesting that venous congestion plays an important role.¹¹ This corresponds with our observation, where at the end of gastric tube reconstruction, the fundus of the stomach often has a bluish colour instead of a pale colour. As an impaired arterial blood supply would lead to a pale appearance of the tissue, whereas venous congestion gives a darker colour of the tissue, we underscribed the hypothesis of venous congestion (*figure 1*).

By using a combination of laser Doppler flow and reflection spectrophotometry to measure microvascular blood flow and microvascular oxygenation, we studied the microvascular blood flow during gastric tube reconstruction. We measured an increase in microvascular haemoglobin concentration and gradual decrease in microvascular haemoglobin saturation. According to our hypothesis this would be expected to occur in the presence of venous congestion. Another argument for a role for venous congestion was that after application of topical nitro-glycerine on the gastric fundus, the gastric microvascular blood flow increased.¹² These results roused our curiosity on the relation between tissue perfusion pressure and venous congestion of the gastric tube. We created a gastric tube reconstruction in a pig model and we used nor-epinephrine to increase mean arterial pressures from 50 to 110 mmHg. In a second group, nor-epinephrine was combined with intravenous nitro-glycerine, in a dosage to keep the central venous pressure

Figure 1. A gastric tube in a pig model, just after the construction of the tube.



below 10 mmHg (*figure 2*). We observed that the combination of nor-epinephrine and nitro-glycerine provides a more improved microvascular perfusion of the gastric conduit than nor-epinephrine alone.¹³ This observation supports our hypothesis of a role for venous congestion in impaired gastric blood flow following gastric tube reconstruction.


The position of the gastroesophageal anastomosis in relation to microcirculation and the limits of the right gastroepiploic arterial arcade seem to be important. In 1946, Ivor-Lewis introduced a technique with an intrathoracic anastomosis of a gastric conduit and the rest of the oesophagus.¹⁴ Unfortunately, leakage of the intrathoracic anastomosis, led to infection of the mediastinum with fatal consequences. Therefore, a technique with a cervical anastomosis was developed.¹⁵ In case of leakage of the cervical anastomosis, drainage to the outside of the neck is often a proper and manageable solution with no great clinical consequences. However, to create a cervical anastomosis a longer and more poorly circulated conduit is necessary. This in return will lead to a greater risk for anastomotic failure. Although most cervical anastomosis leakages are drained to the outside, some may leak into the chest and create infections of the mediastinum as well. Due to the availability of better diagnostic tools, minimal invasive techniques for the management of leakage, and the lower expected incidence of anastomotic failure, the intrathoracic anastomosis has become a procedure of renewed interest in the Netherlands. However, an intrathoracic anastomosis is only suitable for tumours in the lower oesophagus and not for carcinoma in the higher oesophagus and recent analysis failed to provide evidence as to which type of anastomosis is of more benefit to patients.¹⁶ In the treatment of anastomotic leakage, aggressive surgical re-exploration with additional drainage, total parenteral nutrition, nasogastric decompression and broad-spectrum antibiotics are effective, but lead to a prolonged ICU and hospital stay.¹⁷ Occasionally anastomotic repair and reinforcement of the anastomosis with muscle flaps is necessary; the results, however, are poor. To seal anastomotic leakage, recently self-expanding metal or plastic stents in combination with effective drainage seem to be a viable option. However, dislocation of these stents remains a problem.¹⁸

Pulmonary morbidity

Oesophagectomy is highly associated with pulmonary complications. In a recent review postoperative pneumonia was reported in 57% of the studies. Similar to anastomotic leakage, there are many different definitions of pneumonia.¹⁰ Almost all definitions of post-oesophagectomy pneumonia use a combination of radiologic infiltrates, positive culture of sputum, fever, increased white blood count and clinical suspicion for which antibiotics were started.

The incidence of pulmonary complications is associated with age, operation duration, proximal tumour location and

Figure 2. Microvascular blood flow (MBF) measurements on gastric pylorus, corpus and fundus at increasing MAP levels. Data represent mean \pm SEM; # P<0,05 vs CTRL, b P<0,05 vs baseline, ^ P<0,05 vs MAP 50, \$ P<0,05 vs MAP 60.



surgical techniques.¹⁹ During a transthoracic oesophagectomy procedure, one lung is collapsed to allow surgical exposure to the oesophagus. This leads to atelectasis and local contusion of the lung. Prolonged duration of procedure predisposes patients undergoing one lung anaesthesia, to increased atelectasis and respiratory complications. Systemic inflammatory response due to surgical trauma of the other lung, can lead to bilateral lung oedema and acute lung injury.²⁰ Several inflammatory markers including interleukins, tumour necrosis factor and neutrophil endothelial markers are likely to cause persistent injury to the alveolar-capillary barrier function which leads to a shift and accumulation of fluids in the extra vascular space and this induces pulmonary oedema.^{21,22} Minimal invasive oesophagectomy, may reduce the pulmonary complications, leading to a reduced length of ICU and hospital stay.^{23,24}

There is emerging evidence that next to the influence of surgical techniques, anaesthetic management also directly influences the incidence of pulmonary complications.²⁵ Early extubation has been shown to reduce pulmonary complications.²⁶ However, to achieve successful early extubation, effective postoperative analgesia is required.²⁷ Although subject for debate, thoracic epidural analgesia is recommended to intravenous opiates to achieve effective analgesia during oesophagectomy.²⁸ Epidural analgesia provides pain relief, reduces respiratory complications, reduces ICU stay and possibly the mortality rate following oesophagectomy.^{29,30} There is also a beneficial effect of epidural analgesia on the surgical stress response and associated immune function in oesophagectomy.³¹ Effective thoracic epidural analgesia increases tissue oxygenation during abdominal surgery and might improve gastric blood flow following oesophagectomy.³² Regarding all these arguments we still encourage epidural analgesia for oesophagectomy.

The relation between perioperative fluid management on pulmonary complications following major surgery is well documented. In order not to compromise gastric tube

perfusion, perioperative hypotension usually was treated with administration of fluid, thereby avoiding the use of vasoactive medication. As a result, the net fluid balance at times increased in the first 24 hours. In some cases net fluid balance reached up to 10 L. Clinical trials investigating the effect of restrictive fluid management found a reduction in postoperative complications.³³ However, studies using a goal directed fluid management also claim better results. Unfortunately, local differences have led to diverse standards of fluid management; the restrictive treatment in one study is called liberal in the next study.³⁴ Looking specifically at oesophagectomy patients, several studies favour fluid restriction.^{35,36} We have shown in a clinical study that a reduction in administered fluids can reduce pulmonary complications following oesophagectomy without an increased incidence of anastomotic leakage.³⁷

It is surprising that only a few studies have been performed that look at perioperative ventilation strategies aimed at reducing pulmonary morbidity. The use of protective mechanical ventilation using low tidal volume during the one lung ventilation reduces the interleukin-6 levels. High levels of interleukin-6 are associated with adverse outcome following surgery and protective ventilation improves postoperative lung function and results in earlier extubation.^{38,39}

Prolonged perioperative hypoxemia and haemodynamic instability are associated with higher occurrences of pulmonary complications, e.g. acute lung injury and adult respiratory distress syndrome.⁴⁰ Incorrectly positioned double lumen tubes during oesophagectomy have also been noted as a serious contributor to perioperative morbidity.⁴¹ To avoid double lumen tubes or bronchus blockers, we studied the feasibility of two-lung high frequency ventilation. We concluded that two-lung high frequency ventilation is a usable ventilation strategy, although there is no effect on postoperative pulmonary complications.⁴²

Inflammatory pathways

In the previous paragraphs we described the two most important complications following oesophagectomy. In both complications there is a role for the systemic inflammatory response syndrome (SIRS). However, what are the effects of SIRS on morbidity following oesophagectomy?

Increased surgical stress parameters (blood loss/body weight and operation time) correlates with the duration of SIRS, or the number of positive criteria for SIRS post-surgery.⁴³ Morita described the mechanism of an increased inflammatory response post-oesophagectomy in a two hit model. The first hit is the result of great surgical stress, the necrosis and infection around the poorly circulated gastric oesophageal anastomosis, which in return results in the second hit, acute lung injury.⁴⁴ The influence of preoperative neoadjuvant chemoradiotherapy is associated with prolonged or severe SIRS parameters.⁴⁵ However, neoadjuvant chemoradiation does not appear to increase postoperative morbidity or mortality post-oesophagectomy.⁴⁶ There is growing evidence for several agents to reduce SIRS. For example, steroids are recommended in Japanese guidelines.⁴⁷ More recently a neutrophil elastase inhibitor was demonstrated to reduce postoperative pneumonia following oesophagectomy.⁴⁸ Increased plasmatic cytokine levels are characteristic for post-oesophagectomy patients and especially for post-oesophagectomy patients with postoperative infection including pulmonary infection.⁴⁹ Detection during the first 48 h of SIRS criteria, high plasma pro-inflammatory cytokine levels (interleukin 6, tumour necrosis factor alpha) and impairment of PaO₂/FiO₂ predicts the onset of pulmonary complications.⁵⁰ Additionally, increased C-reactive protein concentration (CRP) levels in the early postoperative period, are associated with the occurrence of postoperative complications and increased one year mortality.⁵¹ The production CRP in the liver is stimulated by pro-inflammatory cytokines.

It has been shown that the vagus nerve plays a prominent role in inflammation through the cholinergic anti-inflammatory pathway.⁵² The vagus nerve down-regulates inflammation by decreasing the release of tumour necrosis factor (TNF)- α by macrophages. Activation of the vagus nerve releases acetylcholine in the vicinity of macrophages within the reticulo-endothelial system, leading to the inhibition of cytokine release. Stimulation of the vagus nerve results in decreased cytokine release, whereas vagotomy results in an increase in cytokine release.⁵³ In a recent study, trauma patients who underwent vagotomy developed septicaemia eight times more often than the matched control patients.⁵⁴

Therefore, the presence of an intact vagus nerve and gut innervation will decrease the post-injury inflammatory response. In both trans hiatal and or transthoracic oesophagectomy, acute vagotomy is performed thus deactivating the cholinergic anti-inflammatory pathway. In oesophagectomy, where a cervical

anastomosis is applied, both the vagus nerves are dissected in the upper mediastinum. However, in oesophagectomy with an intrathoracic anastomosis, the higher branches of the vagus nerve are preserved.

In this context, vagal sparing oesophagectomy might play a role in the prevention of post-operative complications. Vagal sparing oesophagectomy is a well-known technique, first described by Akiyama in 1994.⁵⁵ The goal of vagal sparing oesophagectomy is to increase quality of life by preserving postoperative gastric emptying and prevent patients from developing the dumping syndrome and diarrhoea. In later studies, this technique was found to be clinically associated with lower mortality and morbidity.⁵⁶ In vagal sparing oesophagectomy the oesophagus is stripped (inverted) out of the mediastinum. Only a highly selective vagotomy is performed on the gastric-oesophageal junction and the colon is used as an oesophageal substitute.⁵⁷ However, vagal sparing oesophagectomy is only possible in a limited group of patients. These include patients with: end-stage benign oesophageal disease, Barrett's oesophagus with high-grade dysplasia, or multifocal oesophageal cancer limited to the lamina propria.

There is growing evidence that the cholinergic anti-inflammatory response can be stimulated by nutrition. Nutrition should specifically include dietary lipids, these activate the autonomic nervous system through the afferent vagal nerve and lead to the release of neuro-endocrine hormones.⁵⁸ Thus, nutrition may be used as therapy to prevent excessive inflammation.⁵⁹ However, randomized controlled trials are necessary to collect evidence for this interesting hypothesis in the clinical setting from thousands of different individuals, our patients.

Conclusion

Although mortality following oesophagectomy has decreased during the last few decades because of improvements in surgical and perioperative care, the procedure is still associated with high morbidity. Anastomotic failure and pulmonary complications are the most frequent complications. Tissue supportive strategies may reduce the incidence of anastomotic leakage by stimulating the microvascular blood flow of the gastric conduit. Clinical pathways and minimally invasive surgical techniques may influence the rate and severity of pulmonary complications.

The role of SIRS and the cholinergic anti-inflammatory pathway in the pathogenesis of pulmonary complications post-oesophagectomy is a challenging subject for future research. The concentration of highly complex care leads to more experience in the treatment of complications and the development of new multi modal pathways. However, clinical pathways succeed only if surgeons, anaesthetists and intensivists feel that they are part of the process and take responsibility as a team for all complications that occur.

References

1. Kehlet H, Wilmore DW. Multimodal strategies to improve surgical outcome. *Am J Surg.* 2002;183:630-44.
2. Low DE. Evolution in perioperative management of patients undergoing esophagectomy. *Br J Surg.* 2007;94:655-6.
3. Al-Sarira AA, Wilmot DZ, Slavin JP, Deakin M, Corless DJ. Oesophagectomy practice and outcomes in England. *Br J Surg.* 2007;94:585-91.
4. Metzger R, Bollschweiler E, Vallböhmer D, Maish M, DeMeester TR, Hölscher AH. High volume centers for esophagectomy: what is the number needed to achieve to postoperative mortality. *Dis Esophag.* 2004;17:310-4.
5. Brodner G, Pogatzki E, Van Aken H, Buerkle H, Goeters C, Schutzki C, et al. A multimodal approach to control postoperative pathophysiology and rehabilitation in patients undergoing abdominothoracic esophagectomy. *Anesth Analg.* 1998;86:228-34.
6. Low DE, Kunz S, Schmebre D, Otero H, Malpass T, His A, et al. Esophagectomy-It's not just about mortality anymore: standardized perioperative clinical pathways improve outcomes in patients with esophageal cancer. *J Gastrointest Surg.* 2007;11:1395-402.
7. Chandrashekar M, Irving M, Wayman J, Raimes S, Linsley A. Immediate extubation and epidural analgesia allow safe management in a high-dependent unit after two-stage oesophagectomy. Results of eight years of experience in a specialized upper gastrointestinal unit in a district general hospital. *Br J Anaesth.* 2003;90:474-9.
8. Hulscher JB, Van Sandick JW, De Boer AGEM, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. *N Engl J Med.* 2002;347:1662-9.
9. Blencowe NS, Strong S, Mc Nair AGK, Brookes ST, Crosby T, Griffin SM, et al. Reporting of Short Term clinical outcomes after esophagectomy. *Ann Surg.* 2012;255:658-66.
10. Yuan Y, Duranceau A, Farraro P, Martin J, Liberman M. Vascular conditioning of the stomach before esophageal reconstruction by gastric interposition. *Dis Esophagus.* 2012, jan 31 (epub ahead of print).
11. Murakami M, Sugiyama A, Ikegami T, Ishida K, Maruta F, Shimizu F, et al. Revascularization using the short gastric vessels of the gastric tube after subtotal esophagectomy for intrathoracic esophageal carcinoma. *J Am Coll Surg.* 2002;190:71-7.
12. Buise MP, Ince C, Tilanus HW, Klein J, Gommers D, van Bommel J. The effect of nitroglycerin on microvascular perfusion and oxygenation during gastric tube reconstruction. *Anesth Analg.* 2005;100:1107-11.
13. Van Bommel J, De Jonge J, Buise MP, Specht P, van Genderen M, Gommers D. The effects of intravenous nitroglycerine and norepinephrin on gastri microvascular perfusion in an experimental model of gastric tube reconstruction. *Surgery.* 2010;148:71-7.
14. Lewis I. The surgical treatment of carcinoma of the oesophagus: with special reference to a new operation for growths of the middle third. *Br J Surg.* 1946;34:18-31.
15. McKeown KC. Total three-stage oesophagectomy for cancer of the oesophagus. *Br J Surg.* 1976;63:259-62.
16. Kayani B, Jarral OA, Athanasiou T, Zacharakis E. Should oesophagectomy be performed with cervical or intrathoracic anastomosis? *Interactive Cardio Vascular and Thoracic Surgery.* 2012;0:1-6.
17. Sauvanet A, Baltar J, Le Mee J, Belghiti J. Diagnosis and conservative management of intrathoracic leakage after esophagectomy. *Br J Surg.* 1998;85:1446-9.
18. Dai Y, Chopra SS, Kneif S, Hünerbein M. Management of esophageal anastomotic leaks. Perforations and fistulae with self expanding plastic stents. *J Thorac Cardiovasc Surg.* 2011;141:1213-7.
19. Law S, Wong KH, Kwok KF, Chu KM, Wong J. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. *Ann Surg.* 2004;240:791-800.
20. Zingg U, Forberger J, Frey DM, Esterman AJ, Oertli D, Beck-Schimmer B, et al. Inflammatory response in ventilated left and collapsed right lungs, serum and pleural fluid, in transthoracic esophagectomy for cancer. *Eur Cytokine Netw.* 2010;21:50-7.
21. Sato Y, Motoyama S, Maruyama K, Okyama M, Hayashi K, Nakae H, et al. Extravascular lung water measured using single transpulmonary thermodilution reflects perioperative pulmonary edema induced by esophagectomy. *Eur Surg Res.* 2007;39:7-13.
22. Reid PT, Donnelly SC, MacGregor IR, Grant IS, Cameron E, Walker W, et al. Pulmonary endothelial permeability and circulating neutrophil-endothelial markers in patients undergoing esophagogastrectomy. *Crit Care Med.* 2000;28:3161-5.
23. Bier SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Carcia JR, et al. Minimal invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. *Lancet.* 2012, apr 30 (epub ahead of print)
24. Bakhos CT, Fabian T, Oyasijj TO, Gautam S, Gangadharan SP, Kent MS, et al. Impact of surgical technique on pulmonary morbidity after esophagectomy. *Ann Thorac Surg.* 2012;93:221-6.
25. Pennefather SH. Aneesthesia for Oesophagectomy. *Curr Opin Anaesthesiol.* 2007;20:15-20.
26. Lanuti M, de Delva PF, Mahner A, Wright CD, Gaissert HA, Wain JC, et al. Feasibility and outcomes of an early extubation policy after esophagectomy. *Ann Thorac Surg.* 2006;82:2037-41.
27. Cerfolio RJ, Bryant AS, Bass CS, Alexander JR, Bartolucci AA. Fast tracking after Ivor Lewis esophagogastrectomy. *Chest.* 2004;126:1187-194.
28. Ng JM. Update on anaesthetic management for esophagectomy. *Curr Opin Anaesthesiol.* 2011;24:37-43.
29. Rudin A, Flisberg P, Johansson J, Walther B, Lundberg CJ. Thoracic epidural analgesia or intravenous morphine analgesia after thoracoabdominal esophagectomy: a prospective follow-up of 201 patients. *J Cardiothorac Vasc Anesth.* 2005;19:350-7.
30. Cense HA, Lagarde SM, De Jong K, Omluo JM, Bush OR, Henny ChP, et al. Association of no epidural analgesia with postoperative morbidity and mortality after trans thoracic esophageal cancer resection. *J Am Coll Surg.* 2006;202:395-400.
31. Ahlers O, Nachtigall I, Lenze J, Goldmann A, Schulte E, Höhne C, et al. Intraoperative thoracic epidural anaesthesia attenuates stress-induced immunosuppression in patients undergoing major abdominal surgery. *Br J Anaesth.* 2008;101:781-7.
32. Michelet P, Roch A, D'Journo XB, Blayac D, Barrau K, Papazian L, et al. Effect of thoracic epidural analgesia on gastric blood flow after esophagectomy. *Acta Anaesthesiol Scand.* 2007;51:587-94.
33. Brandstrup B, Tønnesen H, Beier-Holgersen R, Hjortso E, Ørding H, Lindorff-Larsen K, et al. The Danish Study Group on Perioperative Fluid Therapy: Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens. *Ann Surg.* 2003;238:641-8.
34. Jacob M, Chappell D, Rehm M. Perioperative fluid administration: another form of "work-life balance". *Anesthesiology.* 2011;114:483-4.
35. Casado D, López F, Martí R. Perioperative fluid management and major respiratory complications in patients undergoing esophagectomy. *Dis Esophagus.* 2010;23:523-8.
36. Neal JM, Wilcox RT, Allen HW, Low DE. Near-total esophagectomy: the influence of standardized multimodal management and intraoperative fluid restriction. *Reg Anesth Pain Med.* 2003;28:328-34.
37. Buise MP, van Bommel J, Mehra M, Tilanus HW, van Zundert A, Gommers D. Pulmonary Morbidity following esophagectomy is decreased after introduction of a multimodal anesthetic regimen. *Acta Anaesth Belg.* 2008;59:257-61.
38. Michelet P, D'Journo XB, Roch A, Doddoli C, Marin V, Papazian L, et al. Protective ventilation influences systemic inflammation after esophagectomy; a randomized controlled study. *Anesthesiology.* 2006;105:911-9.
39. Jawa RS, Annillo S, Huntoon K, Baumann H, Kulayalat M. Interleukin-6 in surgery, trauma, and critical care part 11: clinical implications. *J Intensive Care Med.* 2011;26:73-8.
40. Tandon S, Batchelor A, Bullock R, Gascoigne A, Griffin M, Hayes N, et al. Perioperative risk factors for acute lung injury after elective oesophagectomy. *Br J Anaesth.* 2001;86:633-8.
41. Sherry KM. How can we improve the outcome of oesophagectomy? *Br J Anaesth.* 2001;86:611-3.
42. Buise MP, van Bommel J, van Genderen M, Tilanus HW, van Zundert AA, Gommers D. Two-Lung High-frequency Jet Ventilation as an alternative ventilation technique during Trans Thoracic Esophagectomy. *J Cardiothorac Vasc Anesth.* 2009;23:509-12.
43. Haga Y, Beppu T, Doi K, Nozawa F, Mugita N, Ikei S, et al. Systemic inflammatory response syndrome and organ dysfunction following gastrointestinal surgery. *Crit Care Med.* 1995;25:1994-2000.
44. Morita M, Yoshida R, Ikeda K, Egashira A, Oki E, Sadanaga N, et al. Acute lung injury following an esophagectomy for esophageal cancer, with special reference to the clinical factors and cytokine levels of peripheral blood and pleural drainage fluid. *Dis Esophagus.* 2008;21:30-6.
45. Tsujimoto H, Ono S, Chochi K, Sugawara H, Ichikura T, Mochizuki H. Preoperative chemoradiotherapy for esophageal cancer enhances the postoperative systemic inflammatory response. *Jpn J Clin Oncol.* 2006;36:632-7.

46. Merritt RE, Whyte RI, D'Arcy NT, Hoang CD, Shrager JB. Morbidity and mortality after esophagectomy following neoadjuvant chemoradiation. *Ann Thorac Surg.* 2011;92:2034-40.
47. Kuwano H, Nishimura Y, Ohtsu A, Kato H, Kitagawa Y, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2007 edition: part I. *Esophagus* 2008;5:117-32.
48. Akutsu Y, Matsubara H. Perioperative management for the prevention of post-operative pneumonia with esophageal surgery. *Ann Thorac Cardiovasc Surg.* 2009;15:280-5.
49. Yamada T, Hisanaga M, Nakajima Y, Kanehiro H, Watanabe A, Ohya T, et al. Serum interleukin-6, interleukin-8, hepatocyte growth factor, and nitric oxide changes during thoracic surgery. *World J Surg.* 1998;22:783-90.
50. D'Journo XB, Michelet P, Marin V, Dienes I, Blayac D, Doddoli C, et al. An early inflammatory response to oesophagectomy predicts the occurrence of pulmonary complications. *Eur J Cardiothorac Surg.* 2010;37:1144-51.
51. Van Genderen ME, Lima A, de Geus H, Klijn E, Wijnhoven B, Gommers D, et al. Serum C-reactive protein as a predictor of morbidity and mortality in intensive care unit patients after esophagectomy. *Ann Thorac Surg.* 2011;91:1775-9.
52. Czura CJ, Tracey KJ. Autonomic neural regulation of immunity. *J Intern Med.* 2005;257:156-66.
53. Tracey KJ. The inflammatory reflex. *Nature.* 2002;420:853-9.
54. Peterson CY, Krzyzaniak M, Coimbra R, Chang DC. Vagus nerve and postinjury inflammatory response. *Arch Surg.* 2012;147:76-80.
55. Akiyama H, Tsurumaru M, Ono Y, Udagawa H, Kajiyama Y. Esophagectomy without thoracotomy with vagal preservation. *J Am Coll Surg.* 1994;178:83-5.
56. Lekkaos L, Karidis NP, Dimitroulis D, Tsigris C, Kouraklis G, Nikiteas N. Barrets esophagus with high grade dysplasia: focus on current treatment options. *World J Gastroenterol.* 2011;17:4174-83.
57. Banki F, Mason RJ, DeMeester SR, Hagen JA, Balaji NS, Crookes PF, et al. Vagal-sparing esophagectomy: a more physiologic alternative. *Ann Surg.* 2002;236:324-35.
58. Luyer MDP, Habes Q, van Hak R, Buurman W. Nutritional stimulation of the autonomic nervous system. *World J Gastroenterol.* 2011;17:3859-63.
59. Luyer MD, Greve JWM, Hadfoune M, Jacobs JJ, Dejong CH, Buurman WA. Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. *J Exp Med.* 2005;245:795-802.

Verkorte productinformatie Mycamine® 50 mg/100 mg (januari 2013)

Samenstelling: Mycamine® 50 mg/100 mg poeder voor oplossing voor infusie (in natriumvorm). De toe te dienen hoeveelheid na reconstitutie is 10 mg/ml en 20 mg/ml, resp. (in natriumvorm). **Farmacotherapeutische groep:** Overige antimycotica voor systemisch gebruik, ATC-code: J02AX05. **Therapeutische indicaties:** *Immuusseren, adolescenten ≥ 16 jaar en ouderen:* Behandeling van invasieve candidiasis; Behandeling van oesofageale candidiasis bij patiënten voor wie intraveneuze therapie geschikt is; Prophylaxe van *Candida* infectie bij patiënten die allogene hematopoëtische stamceltransplantatie ondergaan of van wie wordt verwacht dat ze aan neutropenie lijden gedurende 10 dagen of langer. *Kindereen (inclusief neonaten) en adolescenten < 16 jaar:* Behandeling van invasieve candidiasis; Prophylaxe van *Candida* infectie bij patiënten die allogene hematopoëtische stamceltransplantatie ondergaan of van wie wordt verwacht dat ze aan neutropenie lijden gedurende 10 dagen of langer. Bij de beslissing Mycamine te gebruiken dient rekening gehouden te worden met het potentiële risico voor de ontwikkeling van levertumoren. Mycamine dient daarom uitsluitend te worden gebruikt als andere antifungale middelen niet in aanmerking komen. **Dosering en wijze van toediening:** Behandeling van invasieve candidiasis: 100 mg/dag, 2 mg/kg/dag bij een lichaamsgewicht < 40 kg. Als de patiënt in onvoldoende mate reageert, bv. indien de kweken positief blijven of de klinische toestand niet verbetert, dan mag de dosis worden verhoogd tot 200 mg/dag bij patiënten met een lichaamsgewicht > 40 kg of tot 4 mg/kg/dag bij patiënten met een lichaamsgewicht ≤ 40 kg. Prophylaxe van *Candida* infectie: 50 mg/dag, 1 mg/kg/dag bij een lichaamsgewicht < 40 kg. Behandeling van oesofageale candidiasis: 150 mg/dag, 3 mg/kg/dag bij een lichaamsgewicht < 40 kg. **Contraindicaties:** Overgevoeligheid voor het werkzame bestanddeel, voor andere echinocandines of voor één van de hulpstoffen. **Waarschuwingen en voorzorgen bij gebruik:** De ontwikkeling van foci van veranderde hepatocyten (FAH) en hepatocellulaire tumoren werd bij ratten waargenomen na een behandelperiode van 3 maanden of langer. De leverfunctie dient zorgvuldig te worden gecontroleerd tijdens behandeling met micafungine. Om het risico op adaptieve regeneratie en mogelijk daaropvolgende levertumorvorming te minimaliseren, wordt vroegtijdig staken aanbevolen indien significante en persistente verhoging van ALT/AST optreedt. De micafungine behandeling dient uitgevoerd te worden na een zorgvuldige risico/voordelen bepaling, met name bij patiënten met ernstige leverfunctiestoornissen of chronische leverziekten die preneoplastische aandoeningen vertegenwoordigen, of bij het tegelijkertijd ondergaan van een behandeling met hepatotoxische en/of genotoxische eigenschappen. Er zijn onvoldoende gegevens beschikbaar over de farmacokinetiek van micafungine bij patiënten met ernstige leverfunctiestoornissen. Er kunnen anafylactische/anafylactoïde reacties optreden, waarna de infusie met micafungine moet worden stopgezet en de juiste behandeling moet worden ingesteld. Exfoliatieve huidreacties zijn gemeld; als patiënten uitslag ontwikkelen, dienen zij nauwkeurig geobserveerd te worden. De therapie dient gestopt te worden als de laesies verergeren. In zeldzame gevallen is er hemolyse gerapporteerd. In dit geval dient nauwlettend te worden gevolgd of er geen verslechtering optreedt en er dient een risico/baten analyse gedaan te worden van voortzetting van de therapie. Patiënten dienen nauwlettend te worden gecontroleerd op verslechtering van de nierfunctie. Patiënten met zeldzame galactose intolerantie, Lapp lactasedeficiëntie of glucoselactose malabsorptie dienen dit middel niet te gebruiken. **Interacties:** Patiënten die Mycamine in combinatie met sirolimus, nifedipine of itraconazol ontvangen, dienen te worden gecontroleerd op toxiciteit van sirolimus, nifedipine of itraconazol. Gelijktijdige toediening van micafungine met amfotericine B-desoxycholaat is alleen toegestaan wanneer de voordelen duidelijk opwegen tegen de risico's, met een scherpe controle op mogelijke toxiciteit van amfotericine B-desoxycholaat. **Bijwerkingen:** De volgende bijwerkingen deden zich vaak (≥ 1/100 tot < 1/10) voor: leukopenie, neutropenie, anemie, hypokaliëmie, hypomagnesiëmie, hypocalciëmie, hoofdpijn, febitis, misselijkheid, braken, diarree, buikpijn, verhoogd bloedalkaline-fosfatase, verhoogd aspartaataminotransferase, verhoogd alanineaminotransferase, verhoogd bilirubine in het bloed (inclusief hyperbilirubinemie), afwijkende leverfunctietest, uitslag, pyrexie, koude rillingen. Naast bovengenoemde bijwerkingen zijn bij kinderen tevens vaak trombocytopenie, tachycardie, hypertensie, hypotensie, hyperbilirubinemie, hepatomegalie, acuut nierfalen en verhoogd bloeddureum gemeld. In de volledige SPC tekst worden de soms, zelden voorkomende bijwerkingen en bijwerkingen die niet met de beschikbare gegevens kunnen worden bepaald gemeld. **Afleverstatus:** UR. **Overige productinformatie:** Astellas Pharma B.V. Sylviusweg 62, 2333 BE Leiden, PO Box 344, 2300 AH Leiden, phone: +31(0)71 545 57 45, fax: +31(0)71 545 58 00

Referenties: 1. Sinds 2002; aantal patiëntendagen berekend over aantal verkochte Kg (Bron: IMS 12/02-09/12/ gemiddelde dagdosering gedurende 14 aanbevolen behandeling (bron: SmPC). Veronderstelde behandelduur is 14 dagen. 2. SmPC Mycamine 25042008. 13-MYC-003

